New York AG calls for 'more strin­gen­t' Sin­gu­lair safe­ty warn­ings

New York At­tor­ney Gen­er­al Leti­tia James wants an “ur­gent” re­view of the safe­ty la­bel for a decades-old asth­ma and al­ler­gy med­ica­tion.

James last week raised con­cerns about neu­ropsy­chi­atric risks among mi­nors that were pre­scribed mon­telukast, bet­ter known as Sin­gu­lair. In 2020, the FDA added a black box warn­ing, its most se­ri­ous warn­ing, to mon­telukast’s la­bel af­ter re­ceiv­ing re­ports of “ag­i­ta­tion, de­pres­sion, sleep­ing prob­lems, and sui­ci­dal thoughts and ac­tions.” James’ of­fice called that warn­ing “in­suf­fi­cient” in a Feb. 21 let­ter to FDA Com­mis­sion­er Robert Califf.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER